This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

October 26-28, 2021
2:30pm - 5:00pm CETOnline Training Course

Who Should Attend?

  • Medicinal chemists, organic chemists, bioorganic chemists, Discovery Scientists, Therapeutic Areas such as (but not limited too) Oncology, CNS, Cardiovascular, Renal, Metabolism and Respiratory
  • Junior, Senior Scientists and managers involved in the development of therapeutic oligonucleotide conjugates in pharma and biotech companies. (Chemistry: Discovery Sciences, Therapeutic Areas for example: Cardiovascular, Renal, Metabolism, Respiratory)
  • Junior, Senior Scientists and managers that have recently been re-assigned or joined into roles in the development of therapeutic oligonucleotide conjugates in pharma and biotech companies. This as a result of the renewed focus on RNAi, ASO therapeutics.
  • Junior, Senior Scientists and managers that are interested to change roles to become an active player in the development of therapeutic oligonucleotide conjugates in pharma and biotech companies. This as a result of the renewed focus on RNAi, ASO therapeutics.